文档介绍：急性肾损伤的生物标志物
Abstract
One major reason for this lack of success may be the result of delayed implementation due to the inability to detect AKI biomarkers of AKI(creatinine and urea)do not detect injury early enough. Thus,It is a priority to find reliable,early biomarkers that predict subsequent AKI.
其中主要原因是缺乏早期诊断AKI的措施。传统的AKI生物标志物（肌酐和尿素氮）不能早期诊断损伤。所以，急需寻找可靠、可早期预示AKI的生物标志物。
Abstract
Innovative technologies such as functional genomics and proteomics have facilitated detection of several promising early biomarkers of AKI,such as neutyophil gelatinase-associated lipocalin(NGAL),cystatin C(CyC), liver-type fatty acid binding protein(L-FABP),interleukin-18(IL-18),and kidney injury molecule-1(KIM-1).
新技术如功能基因组学和蛋白组学已帮着发现了几种有前景的，可早期提示AKI的生物标志物，如人中性粒细胞明胶酶相关脂质运载蛋白（NGAL）、半胱氨酸蛋白酶抑制剂C（CyC）、肝脏型脂肪酸结合蛋白（L-FABP）、白介素18（IL-18）和肾损伤分子1（KIM-1）。
Abstract
These biomarkers have many potential applications function,as safety markers to monitor toxicity and as measures of treatment example,NGAL and cystatin C have been used in a safety monitoring trial of hydroxyethylstarch therapy and to detect AKI early,during or immediately after cardiac use beyond research settings is rapidly expanding.
这些生物标志物在麻醉科和ICU中有很多潜在的应用。它们可用于评估新技术和治疗在肾功能上的影响，监测肾中毒程度和治疗效果。比如，NGAL和CyC已经用于一心脏手术期间羟乙基淀粉治疗安全监测试验以及早期预测AKI。
Key words
Kidney failure Creatinine Urea Biological markers Lipocalins
Cystatin C Fatty acid binding protein Interleukin-18
肾衰竭 肌酐 尿素氮 生物学标志物 脂质运载蛋白 半胱氨酸蛋白酶抑制剂C 脂肪酸结合蛋白 白介素18
AKI is common with major surgery and critical illness
AKI is the consensus term now used to describe the continuum of the condition previously called acute renal as classified by the RIFLE criteria(acronym for Risk,Injury,Failure, Loss and Endstage)has been reported to occur in approximately 36% of critically ill patients and is common after major surgery such as open heart surgery.
急性肾损伤（AKI）是一个共识性名称，目前用于描述以前叫急性肾衰竭的连续性过程。AKI被报道发生于约3